Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma
about
Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13)Genetics and genomics of radiotherapy toxicity: towards predictionHZE Radiation Non-Targeted Effects on the Microenvironment That Mediate Mammary CarcinogenesisPersonalized Cancer Risk Assessments for Space Radiation ExposuresSecond malignant neoplasms and cardiovascular disease following radiotherapy.Solid tumor second primary neoplasms: who is at risk, what can we do?The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevanceA meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locusPediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.Radiogenomics: radiobiology enters the era of big data and team science.Triple jeopardy for Hodgkin lymphoma survivors?Limited evidence for parent-of-origin effects in inflammatory bowel disease associated lociCurrent knowledge and future research directions in treatment-related second primary malignancies.Minimizing second cancer risk following radiotherapy: current perspectives.Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors.Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivorsc-MYC is a radiosensitive locus in human breast cellsMolecular pathogenesis of secondary acute promyelocytic leukemiaSubsequent malignant neoplasms after hematopoietic cell transplantation.Secondary Malignancies Following Treatment for Hodgkin's Lymphoma in Childhood and AdolescencePredicting outcomes in radiation oncology--multifactorial decision support systemsLeveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational researchSTROGAR - STrengthening the Reporting Of Genetic Association studies in Radiogenomics.Secondary Neoplasms in Children with Hodgkin's Lymphoma Receiving C-MOPP and Radiotherapy: Presentation of Four Cases.Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating riskDoes radiation-induced c-MYC amplification initiate breast oncogenesis?Clinical Guidelines for the Care of Childhood Cancer Survivors.Childhood cancer survivorship research in minority populations: A position paper from the Childhood Cancer Survivor Study.Childhood cancer survivorship: an update on evolving paradigms for understanding pathogenesis and screening for therapy-related late effects.Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis.Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy.A population-based comparison of second primary cancers in Germany and Sweden between 1997 and 2006: clinical implications and etiologic aspects.Genetic predisposition to radiation-related cancer and potential implications for risk assessment.Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment.Neurocognitive function after radiotherapy for paediatric brain tumours.Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.Radiogenomics: the search for genetic predictors of radiotherapy response.
P2860
Q21134099-1F1FDCC0-6CC1-481E-90E3-556A7F7F39BCQ21183971-A94CED6F-DE79-4245-B62C-701485A4D999Q26750868-BA027504-081C-4B08-91FF-AE069A2B354BQ26768260-8AF7BCAD-2167-401D-85AB-3BB28AE605C1Q26864522-DD6F7A58-0006-4B73-AFC2-DC194EDA679AQ27026266-27E1F855-73F9-4E48-8453-C7A3095B8FFBQ28074414-4A581388-B56C-49D7-BC9B-60AFBBC27D6AQ28943487-B62F946D-EA45-4C45-8C85-40CB06E89517Q30248284-B9BA4F28-CCF4-451F-839D-1BC205945FD7Q30833608-41DD8831-7711-4A0A-AA9A-F503D07C0A18Q33917146-A4791EA3-EDF8-4EB9-822F-E04DEF209868Q34428615-5A841358-470F-4DCC-ABE8-8B6B316EE6C7Q34604460-97244987-AEE5-4B99-9B92-0EA9618B439AQ34757180-BA8D72D2-D4B5-42BE-9EF0-F8C1767F6A6CQ35117677-13F6A8A8-C699-40A1-9F55-BEC9107ED422Q35327266-B0B4F53F-91B7-4265-B441-9A818D916543Q35348121-C778B697-847B-4419-BB82-794D22A96CF5Q35560260-1790C14F-B648-43D7-921C-5F1AE2C31196Q35678455-CD4F3E10-D173-4CB2-AD5A-0F4DBF0D9CABQ35682335-74554343-0E36-43CF-B324-825A1F64A02EQ36014711-EECCD475-B336-4C9D-A099-E1A1CC30311BQ36535678-76F8E369-32EB-492B-A6CD-1703E36007B4Q36672778-1F1CAF8A-1A27-4831-B8C5-8048BC064E54Q36722784-A511D14B-D4E3-4D27-8A9F-ED873CBC684AQ36736612-65C605DB-7E39-45CA-86C0-F88243BFC766Q36836096-82412415-F28B-4D8B-8B1C-8B93855899C0Q37055826-67F88D32-E2CC-47D2-9226-BA9F991EC39DQ37116007-BBA39ED6-BC74-40D2-9587-CE8EC60B3BF2Q37167767-E7BE929B-BEB1-49CF-A5B7-AB1DA5F6FF4DQ37207597-86DA1BFF-D1A6-413E-A502-C6703F43A8E0Q37219761-4890FAA9-744B-4534-8169-7EC538A45E4FQ37457332-EC64F5D9-B989-4A38-BACB-61982F298341Q37482598-E30DA309-2304-4167-9298-4E42E6E33711Q37564554-956797D4-27FB-44B7-997D-1C5F8166E097Q37624254-BED74D0A-D302-419A-8C70-5AEC554AFAC8Q37727786-92F3C0BF-2E72-4F89-8F9B-D2EF63998DB2Q38042263-1A8BA970-5F47-4203-A76E-1B2E5F4491D6Q38068839-290A5F31-E057-42FB-B8B2-10157FAA23E2Q38093037-E63C5C3B-9E35-4FCE-9AF7-A1428CFC1273Q38294605-61882004-D1E1-4AB3-AE70-8D072E34CAFD
P2860
Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Variants at 6q21 implicate PRD ...... ncies after Hodgkin's lymphoma
@ast
Variants at 6q21 implicate PRD ...... ncies after Hodgkin's lymphoma
@en
Variants at 6q21 implicate PRD ...... ncies after Hodgkin's lymphoma
@nl
type
label
Variants at 6q21 implicate PRD ...... ncies after Hodgkin's lymphoma
@ast
Variants at 6q21 implicate PRD ...... ncies after Hodgkin's lymphoma
@en
Variants at 6q21 implicate PRD ...... ncies after Hodgkin's lymphoma
@nl
prefLabel
Variants at 6q21 implicate PRD ...... ncies after Hodgkin's lymphoma
@ast
Variants at 6q21 implicate PRD ...... ncies after Hodgkin's lymphoma
@en
Variants at 6q21 implicate PRD ...... ncies after Hodgkin's lymphoma
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Variants at 6q21 implicate PRD ...... ncies after Hodgkin's lymphoma
@en
P2093
Andrew D Skol
David V Conti
Kenan Onel
Leslie L Robison
Louise C Strong
R Stephanie Huang
Sarah A Jackson
Smita Bhatia
Thomas M Mack
P2860
P2888
P3181
P356
10.1038/NM.2407
P407
P577
2011-08-01T00:00:00Z
P5875
P6179
1035119593